Ovarian endometrioid adenocarcinomas (OEAs) frequently exhibit constitutive activation of canonical WNT signaling, usually as a result of oncogenic mutations that stabilize and dysregulate the b-catenin protein. In previous work, we used microarray-based methods to compare gene expression in OEAs with and without dysregulated b-catenin as a strategy for identifying novel b-catenin/TCF target genes with important roles in ovarian cancer pathogenesis. Among the genes highlighted by the microarray studies was MSX2, which encodes a homeobox transcription factor. We found MSX2 expression was markedly increased in primary human and murine OEAs with dysregulated b-catenin compared with OEAs with intact b-catenin regulation. WNT pathway activation by WNT3a ligand or GSK3b inhibitor treatment potently induced MSX2 and ectopic expression of a dominant negative form of TCF4 inhibited MSX2 expression in ovarian cancer cells. Chromatin immunoprecipitation studies demonstrated that b-catenin/ TCF directly regulates MSX2 expression via binding to TCF binding elements in multiple regions of the MSX2 gene. Notably, ectopic MSX2 expression was found to promote neoplastic transformation of the rodent RK3E model epithelial cell line and to enhance the invasiveness of immortalized human ovarian epithelial cells in vitro and ovarian carcinoma cells in vivo. Inhibition of endogenous MSX2 expression in ovarian endometrioid cancer cells carrying a b-catenin mutation using shRNA approaches inhibited neoplastic properties of the cells in vitro and in vivo. Expression of MSX2 in selected ovarian carcinoma cells induced changes suggestive of epithelial-mesenchymal transition (EMT), but based on analysis of ovarian cell lines and primary tumor tissues, effects of MSX2 on EMT appear to be complex and context-dependent. Our findings indicate MSX2 is a direct downstream transcriptional target of b-catenin/TCF and has a key contributing role in the cancer phenotype of OEAs carrying WNT/b-catenin pathway defects.
Introduction
Ovarian endometrioid adenocarcinoma (OEA) is the second most common type of ovarian cancer. We and others have previously shown that 16-38% of OEAs have constitutive activation of the canonical (b-catenindependent) WNT signaling pathway, usually as a result of oncogenic mutations in the b-catenin protein or, less commonly, due to inactivating mutations in key negative regulators of b-catenin such as the APC and AXIN tumor suppressor proteins (Gamallo et al., 1999; Sagae et al., 1999; Wright et al., 1999; Wu et al., 2001; Catasus et al., 2004) . The mutations lead to stabilization of b-catenin and increases in the 'free' pool of b-catenin in the cytoplasm and nucleus. In the nucleus, b-catenin binds to TCF/LEF transcription factors, leading to altered transcription of b-catenin/TCF-regulated target genes, a subset of which likely has critical roles in neoplastic transformation.
Many candidate b-catenin/TCF-regulated target genes have been proposed (summarized at http://www. stanford.edu/Brnusse/pathways/targets.html). However, the role of the vast majority of candidate b-catenin/TCF target genes in the pathogenesis of OEAs is poorly understood. As a strategy for identifying novel WNT pathway target genes that have a functional role in ovarian cancer development and progression, we have used high-density oligonucleotide microarrays to compare gene expression profiles of OEAs with and without dysregulated b-catenin (Schwartz et al., 2003) . Using this approach, two members of the fibroblast growth factor family, FGF9 and FGF20, both of which showed highly upregulated expression in the WNT pathway-defective tumors, were shown to be downstream targets of bcatenin/TCF with important roles in OEA pathogenesis (Chamorro et al., 2005; Hendrix et al., 2006) .
Another gene highlighted by our array-based approaches was MSX2, a member of the homeobox protein family that is also known as HOX-8. MSX2 is a transcriptional regulator with an essential role in embryonic development (Satokata et al., 2000) . Previous studies have suggested MSX2 can function as a downstream effector and upstream regulator of WNT and BMP signaling (Willert et al., 2002; Hussein et al., 2003; Ramos and Robert, 2005; Shao et al., 2005; Song et al., 2009) , though in-depth insights into the means by which MSX2 could function in these varied roles were not offered. It has also been suggested that MSX2 may contribute to the malignant phenotype of breast and pancreatic carcinomas, perhaps through induction of an epithelial-mesenchymal transition (EMT) (Satoh et al., 2008; di Bari et al., 2009) . The role of MSX2 in ovarian cancer pathogenesis is not explored as yet. In the current study, we present data indicating that MSX2 is a direct b-catenin/TCF target gene with a key role in the molecular pathogenesis of a substantial fraction of OEAs.
Results
MSX2 transcripts and protein are highly expressed in primary OEAs with WNT signaling pathway defects As a means of identifying novel candidate b-catenin/ TCF-regulated target genes with roles in OEA pathogenesis, we used high-density oligonucleotide microarrays to compare gene expression patterns in primary human OEAs with and without dysregulated b-catenin. Tumors were classified as having 'dysregulated' b-catenin based on immunohistochemical stains showing nuclear b-catenin expression and/or identification of biallelic inactivating APC mutations (one case) or activating CTNNB1 mutations (all other cases). Tumors were classified as having 'intact' b-catenin regulation if immunohistochemical stains showed membranous expression of b-catenin protein and DNA sequencing failed to identify CTNNB1 mutations (Schwartz et al., 2003; Wu et al., 2007) . MSX2 transcripts were greater than ninefold higher in the OEAs with dysregulated b-catenin relative to tumors with intact b-catenin regulation ( Figure 1a ). MSX1 transcripts were also Bthreefold higher, on average, in OEAs with dysregulated b-catenin, but several tumors with intact b-catenin regulation also showed high levels of MSX1 expression (Supplementary Figure S1A) . To evaluate MSX2 protein expression in OEAs with and without b-catenin dysregulation, we performed immunohistochemical staining for MSX2 using formalin-fixed, paraffin-embedded tissue sections from 30 of the 38 OEA samples used for the earlier expression profiling studies. The b-catenin immunostaining and mutational analyses for CTNNB1, PIK3CA, and APC have been reported previously for these tumors (Wu et al., 2001 (Wu et al., , 2007 Zhai et al., 2002) . Cases with mutations predicted to dysregulate b-catenin showed nuclear accumulation of b-catenin protein, and of these, the vast majority showed moderate or strong MSX2 expression ( Figure 1b and Table 1 ). Two OEAs with presumptive activation of canonical WNT signaling on the basis of nuclear accumulation of b-catenin protein, but lacking CTNNB1 exon 3 mutations, also showed strong ( þ þ ) MSX2 expression. Only one of 13 OEAs with intact b-catenin regulation and exhibiting membranous bcatenin expression showed similarly strong MSX2 expression. Hence, in primary OEAs, strong MSX2 expression is highly correlated with dysregulated bcatenin (P ¼ 0.0024, two-tailed Fisher's exact test). We also evaluated MSX2 expression in several ovarian carcinoma-derived cell lines by western blot (Figure 1c ). Highest expression of MSX2 was identified in the Msx2 Expression (base -2 log) 6 7 8 9  1 0  1 1   OVCAR3  OVCAR5  SKOV3  ES2  TOV21G  MDAH2774  TOV112D   PEO4  OVCA429  OVCA432  OVCA433   43kDa   43kDa   34kDa   0   2000   4000   6000   8000   10000   12000   11T  12T  14T  15T  16T  20T  24T  25T  28T  31T  33T  58T  59T  60T  61T  63T  66T  68T  69T  73T  76T  80T  101T  104T  2T  13T  17T  18T  19T  32T  37T  44T  47T  48T  55T  71T  102T  103T  107T MSX2 Probe Set2
MSX2 Probe Set1
Intact β-catenin regulation Dysregulated β-catenin Relative MSX2 expression WNT target gene MSX2 in ovarian carcinoma Y Zhai et al OEA-derived cell line TOV112D, which has an activating mutation in CTNNB1 (Wu et al., 2001) . MSX2 expression was also readily observed in the SKOV3 and TOV21G cell lines, and low but detectable levels of MSX2 were observed in MDAH2774, OVCA429 and OVCA433. MSX2 expression was not detectable in the five remaining lines (Figure 1c ). In addition to strong correlation of dysregulated b-catenin with elevated MSX2 expression, we noted that primary OEAs (Table 1) and ovarian carcinoma-derived cell lines known to have PIK3CA mutations (SKOV3, TOV21G and OVCA429) (Whyte and Holbeck, 2006; Kuo et al., 2009 ) also showed elevated expression of MSX2. However, several of these samples also harbored CTNNB1 mutations, and the collection of PIK3CA mutant tumors and cell lines was too limited to determine if PI3K activation was independently correlated with increased MSX2 expression. 
MSX2 expression is markedly upregulated in APC

/PTEN
À tumors has been previously published (GSE5987) (Wu et al., 2007) , whereas the full data set from the KRAS mut /PTEN À tumors will be analyzed and published separately. We consistently found marked upregulation of Msx2 transcripts in the APC À /PTEN À murine tumors compared with whole normal ovary samples or the KRAS mut /PTEN À tumors (Figure 1d ). Hence, data from these two murine models of OEA provide further support for the notion that Msx2 is a transcriptional target of b-catenin/TCF signaling and not simply upregulated in ovarian cancer independent of the particular gene mutations, which promote OEA development.
MSX2 is regulated by WNT/b-catenin signaling in ovarian epithelial cells
In an effort to establish that MSX2 expression is regulated by WNT-dependent signaling, we evaluated whether treatment of human ovarian epithelial cells with 
Abbreviations: C, cytoplasmic; M, membranous; N, nuclear; ND, not detected; NP, APC and AXIN2 mutation analysis not performed; WT, wild type.
WNT target gene MSX2 in ovarian carcinoma Y Zhai et al a prototypical WNT ligand that activates the canonical WNT signaling pathway could upregulate MSX2 expression. IOSE80, an immortalized but non-tumorigenic ovarian epithelial cell line, was treated with 50 ng/ml of recombinant mouse WNT3a for 8 h, and significantly increased MSX2 transcripts were observed after WNT3a treatment ( Figure 2a ). As expected, expression of several well-established b-catenin/TCF target genes (AXIN2, LGR5 and BMP4) also increased following WNT3a treatment of IOSE80 cells (Supplementary Figure S2A ). GSK3b has a central role in the destruction complex regulating the free pool of b-catenin in the absence of WNT ligand stimulation. Hence, we next assessed MSX2 expression in MDAH2774 cells following treatment with the GSK3b inhibitor SB216763 (Coghlan et al., 2000; Bommer et al., 2010) . These cells were chosen because they express low, but detectable levels of MSX2 at baseline. A timedependent increase of MSX2 transcripts was observed following SB216763 treatment ( Figure 2b ). To further investigate whether MSX2 is a downstream transcriptional target of b-catenin/TCF, we evaluated MSX2 expression in TOV112D cells stably expressing a dominant-negative version of TCF4 (dnTCF4), which is known to diminish the transcriptional activity of TCF-responsive promoters Leung et al., 2002) . Figure S2B) . Notably, MSX1 transcripts were not increased by stimulation of IOSE80 cells with WNT3a, and expression of dnTCF in TOV112D cells did not inhibit MSX1 expression (Supplementary Figures S1B and S1C). Hence, unlike MSX2, MSX1 does not appear to be a direct downstream target of activated WNT signaling in our system. To determine whether MSX2 is likely to be a direct, rather than indirect b-catenin/TCF target gene, we searched the MSX2 genomic locus and flanking DNA sequences for consensus TCF/LEF-binding elements (WWCAAWG, W ¼ A/T). We found several putative binding sites at the MSX2 locus ( Figure 2d ). Chromatin immunoprecipitation (ChIP) assays were performed using TCF4 antibody to analyze chromatin isolated from TOV112D cells. A known TCF/LEF binding site in the promoter of AXIN2, a well-established direct bcatenin/TCF target gene, was used as a positive control for the anti-TCF4 ChIP assay, whereas irrelevant sites B500 kb downstream of the MSX2 locus (Non-1 and Non-2) and at the RPL30 locus on a different chromosome than MSX2 served as negative controls (Figure 2d , inset). DNA isolated from the anti-TCF4 ChIP of TOV112D cells was seven to 10-fold enriched for three of nine MSX2 sequences containing consensus TCF4 binding sites (Figure 2d ). Studies by others have shown that clusters of TCF binding sites spanning several kilobases of DNA, rather than individual TCF sites, act as WNT response elements (Parker et al., 2008) . In keeping with this notion, Jho et al., (2002) have shown that several TCF/LEF consensus binding sites in the promoter and first introns of AXIN2 (a wellestablished b-catenin/TCF target gene), are important for TCF-mediated activation of AXIN2 expression. Hence, it is not unexpected that TCF4 was found to bind more than one TCF consensus binding site at the MSX2 locus. Collectively, the gene expression and ChIP data suggest that MSX2 is indeed directly regulated by b-catenin/TCF in OEA cells.
MSX2 promotes neoplastic transformation of epithelial cells
Like other b-catenin/TCF target genes with well-known or presumptive oncogenic activity in cancers with defective b-catenin/TCF signaling, such as c-MYC, cyclin D1, and FGFs 9 and 20, we wished to test whether MSX2 might have key roles in cancer-associated phenotypes. To assess the ability of MSX2 to promote neoplastic transformation, we performed focus formation assays using the immortalized rat epithelial cell line RK3E. Cancer-derived mutant forms of b-catenin, as well as several other known oncogenes (for example, GLI1, mutant KRAS), readily generate foci of morphologically transformed cells when introduced into RK3E cells (Kolligs et al., 1999 Hendrix et al., 2006) . Although transformation assays traditionally have been conducted in NIH3T3 fibroblasts, we consider RK3E cells more suitable for our experiments because they are epithelial rather than fibroblastic. Ectopic expression of MSX2 efficiently induced foci in RK3E cells within 2 weeks (Figure 3a ). MSX2-induced focus formation was minimally inhibited in RK3E cells expressing the dnTCF4 mutant protein, whereas the ability of S33Y mutant b-catenin to induce foci in RK3E was potently inhibited by dnTCF4. Inhibitory effects of dnTCF4 on b-catenin/TCF-dependent transcription in RK3E cells was confirmed by showing the expected downregulation of target genes AXIN2, LGR5 and CD44 (Supplementary Figure S2C) . RK3E cells expressing b-catenin (S33Y) showed the expected upregulation of target genes AXIN2 and LGR5 (Supplementary Figure S2D ). clonal RK3E lines expressing MSX2 (n ¼ 10) exhibited anchorage-independent growth in soft agar (Figure 3b ).
short-hairpin RNAs (shRNA)-mediated knockdown of MSX2 inhibits proliferation of ovarian carcinoma cells To further establish the function of MSX2 in ovarian cancer pathogenesis, we utilized shRNA approaches to inhibit MSX2 in two human ovarian cancer cell lines with elevated endogenous MSX2 expression. TOV112D and TOV21G cells were each transduced with three independent shRNA constructs, targeting different regions of the MSX2 transcript. Stable polyclonal cell populations expressing the shRNAs were obtained, and substantial knockdown of MSX2 was achieved in each of the two cell lines using at least two independent shRNAs (Figure 4a ). MSX2 knockdown significantly inhibited the in vitro growth of TOV112D and TOV21G cells (Figure 4b ). Colony formation in soft agar was also significantly reduced in TOV112D cells expressing MSX2 shRNAs relative to the shRNA control (Figure 4c ). To test whether MSX2 knockdown affected growth of ovarian carcinoma cells in vivo, polyclonal TOV112D cell populations stably expressing the two independent shRNAs were also tested for tumorigenicity in nude mice. Subcutaneous tumors formed at five of seven sites injected with control-transduced TOV112D cells (TOV112D/shc), three of six sites injected with cells expressing sh1 (TOV112D/sh1) and four of seven sites injected with cells expressing sh2 (TOV112D/sh2). Average tumor volume at 3 weeks was significantly smaller in tumors arising from TOV112D cells expressing the MSX2 shRNAs (Figure 4d ).
MSX2 promotes invasion of ovarian epithelial cells
Previous work suggested that deregulation of MSX2 may have a significant role in promoting invasion in mouse mammary epithelial cell line-derived tumors (di Bari et al., 2009) . We investigated whether MSX2 could promote invasion of ovarian epithelial cells using Matrigel-coated transwells. The invasive properties of polyclonal IOSE80 cell populations expressing MSX2 were compared with a control IOSE80 cell population transfected with vector alone. Ectopic MSX2 expression led to a significant (P ¼ 0.001) increase in the number of invasive cells (Figure 5a ). To confirm effects of MSX2 on ovarian epithelial cell invasiveness, PEO4 cells (which lack endogenous expression of MSX2) expressing vector alone (neo) or exogenous MSX2 were examined for invasion into the chick chorioallantoic membrane (CAM). This in vivo assay closely mimics invasion of neoplastic epithelial cells through the basement membrane into underlying stroma. Ectopic expression of MSX2 in PEO4 cells enhanced tumor cell invasiveness (Figure 5b) .
We noted that ectopic expression of MSX2 in IOSE80 cells appeared to induce a fibroblast-like morphological change, with features akin to EMT. Similar, but less pronounced effects were noted in PEO4 and OVCA433 cells (Figure 5c ). In IOSE80 cells, the morphological changes were accompanied by a modest increase in (Figure 5d ). N-cadherin and E-cadherin levels following overexpression of MSX2 in IOSE80 cells were unaffected. Ectopic expression of MSX2 in PEO4 cells resulted in increased N-cadherin and vimentin expression, and a slight reduction in E-cadherin expression (Figure 5d ). Despite the data from IOSE80 and PEO4 cells suggesting that MSX2 might alter some markers of EMT, the findings could not be readily generalized to all cell lines studied. Overexpression of MSX2 in OVCA433, another ovarian carcinoma cell line with low levels of endogenous MSX2, led to reduced N-cadherin and vimentin expression and no apparent change in E-cadherin. Activation of WNT signaling via WNT3a stimulation or expression of mutant b-catenin in IOSE80, PEO4 or RK3E cells (Supplementary Figure  S3A) as well as knockdown of endogenous MSX2 in TOV112D cells (Supplementary Figure S3B) likewise resulted in variable effects on EMT markers. Importantly, levels of exogenously expressed MSX2 in IOSE80, PEO4, and OVCA433 were comparable to physiological levels of endogenous MSX2 in TOV112D (Supplementary Figure S3C) .
To more thoroughly address the relationship of dysregulated b-catenin with expression of MSX2 and markers of EMT, we used immunohistochemical staining to evaluate expression of MSX2, E-cadherin, N-cadherin, Vimentin, Snail and Slug in primary OEAs with and without dysregulated b-catenin (n ¼ 6 per group). The additional data are summarized in Supplementary Table  S2 and representative immunostaining is shown in Supplementary Figure S4 . We found that five of six OEAs with dysregulated b-catenin and elevated MSX2 expression expressed vimentin compared with none of the OEAs with intact b-catenin regulation. Although the increased vimentin staining in the b-catenin mutant tumors is suggestive of EMT induced by MSX2, other EMT markers failed to show consistent patterns of differential expression between the two tumor groups. Moreover, tumors with wild-type b-catenin but increased MSX2 expression (for example, OE 79T) did not show increased vimentin expression. Hence, MSX2 expression is not consistently correlated with EMT markers in primary tumor specimens. Collectively, our data suggest that MSX2's role in promoting EMT appears to be complex and context-dependent.
Discussion
Homeobox (HOX) genes encode transcription factors, which function as important regulators of embryonic morphogenesis and differentiation. Specific HOX genes also have roles in cancer pathogenesis, and their altered expression has been described in several different tumor types, including lung, prostate, breast, colorectal, colon and ovarian cancers (Shah and Sukumar, 2010) . Some HOX genes regulate Mu¨llerian duct differentiation and specify morphological identity within the female reproductive tract; these HOX genes may also have a key role in ovarian carcinogenesis as a result of their aberrant expression . Vertebrate muscle segment homeobox (Msx) genes are one of the most highly conserved families of homeobox genes involved in developmental processes, and Msx genes may also be involved in tumorigenesis (Bendall and Abate-Shen, 2000; Satokata et al., 2000; Satoh et al., 2004 ). An earlier study showed MSX2 expression is elevated in a variety of carcinoma cell lines (Suzuki et al., 1993) , and more recent studies have reported MSX2 might enhance pancreatic cancer cell aggressiveness through the induction of an EMT (Satoh et al., 2008) . Interestingly, several studies have suggested that MSX2 can function as both a downstream effector and upstream regulator of WNT and BMP signaling (Willert et al., 2002; Hussein et al., 2003; Ramos and Robert, 2005; Shao et al., 2005; Song et al., 2009 ). In addition, MSX2 expression has been linked to activated MAPK signaling because antisense MSX2 cDNA was found to interfere with the transforming activities of KRAS (Takahashi et al., 1996) . In the current study, we found that MSX2 expression is significantly correlated with dysregulation of WNT/b-catenin/TCF signaling in OEAs. We also found that Msx2 mRNA levels are markedly upregulated in APC À /PTEN À murine ovarian carcinomas, but not in KRAS mut /PTEN À murine carcinomas or normal ovary samples. Hence, in contrast to the findings of Takahashi et al., our results indicate that MSX2 is a downstream target of activated b-catenin/ TCF, but not KRAS/MAPK signaling, in ovarian epithelial cells. This argument is further supported by our in vitro studies showing that WNT signaling pathway activation, either via WNT3a ligand or GSK3b inhibitor treatment, enhances MSX2 transcript levels. Overexpression of a dominant-negative mutant of TCF4 inhibits MSX2 expression. Significantly, chromatin immunoprecipitation assays revealed that TCF4 binds several LEF1/TCF binding sites at the endogenous MSX2 locus. Collectively, our data provide strong support for the proposal that MSX2 is a direct b-catenin/TCF target gene and are consistent with previous studies suggesting that MSX2 is a direct downstream target of activated WNT/b-catenin signaling in human embryonic carcinoma cells and in mouse embryo development during lip formation or fusion (Willert et al., 2002; Song et al., 2009) .
MSX2 has been reported to have a role in regulating the differentiation and/or proliferation of epithelial cells as well as osteogenic cells (Dodig et al., 1999; Jiang et al., 1999) . In addition, MSX2 stimulates pancreatic cancer cell proliferation in vitro and promotes branching morphogenesis of mouse mammary ducts (Satoh et al., 2004 (Satoh et al., , 2008 . We showed that MSX2 promotes neoplastic transformation of E1A-immortalized epithelial cells (RK3E). Diminished MSX2 expression by shRNAmediated knockdown in ovarian carcinoma cell lines inhibited cell proliferation and anchorage independent growth in vitro, and tumor growth in vivo.
Previous studies have also addressed effects of MSX2 on cellular properties that are of likely significance in cancer progression, such as motility and invasiveness, and it has been suggested that MSX2 may have a role in induction of EMT (Satoh et al., 2008; di Bari et al., 2009) . In our work, immortalized human ovarian surface epithelial cells ectopically expressing MSX2 indeed showed increased invasiveness and morphological changes reminiscent of EMT, accompanied by increased vimentin expression compared with cells transduced with vector alone. PEO4 cells transduced with MSX2 showed reduced expression of E-cadherin, a marker of epithelial differentiation, with concomitant increased expression of the mesenchymal markers N-cadherin and vimentin. Notably, similar findings were not observed in OVCA433 and we did not observe upregulation of Cripto-1 or Twist in IOSE80 or PEO4 overexpressing MSX2 (data not shown), which has been reported in other systems (Satoh et al., 2008; di Bari et al., 2009) . Clearly, much remains to be determined regarding the role of MSX2 in promoting EMT, as MSX2's effects appear to be context-dependent.
In conclusion, our findings provide evidence that MSX2 is a direct downstream target of WNT signaling in human OEAs and a mouse model of ovarian endometrioid carcinoma based on conditional WNT signaling activation. We have shown that MSX2 has robust oncogenic properties in epithelial cells, including the ability to promote neoplastic transformation, facilitate anchorage-independent cell growth and enhance invasiveness. Taken together, the findings support a key role for MSX2 in the development and progression of OEAs arising in the context of deregulated WNT signaling.
Materials and methods
Cell lines and drug treatment RK3E (E1A-immortalized rat kidney epithelial cells) and ovarian carcinoma cell lines SKOV3, ES2, TOV21G, MDAH2774 and TOV112D were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA); OVCAR3, OVCAR5 and PEO4 were a gift from T Hamilton (Fox Chase Cancer Center, Philadelphia, PA, USA); OVCA429, OVCA432 and OVCA433 were a gift from D Fishman (Northwestern University, Chicago, IL, USA). The cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and penicillin/streptomycin. IOSE80 cells (human ovarian surface epithelial cells immortalized with SV40 LgTAg) were a gift from N Auersperg (University of British Columbia, Vancouver, Canada). Polyclonal TOV112D and RK3E cell lines expressing dominant-negative TCF-4 (dnTCF4) were obtained after retroviral transduction with supernatants from amphotrophic Phoenix cells transfected with pPGS-dnTCF4 as previously described Leung et al., 2002; Schwartz et al., 2003) . Stable polyclonal lines were maintained in G418 at a concentration of 0.4-0.5 mg/ml. To assess effects of activated WNT/b-catenin signaling on MSX2 gene expression, IOSE80 cells were treated with 50 ng/ml of mouse WNT3a (R&D Systems, Minneapolis, MN, USA) or phosphatebuffered saline for 8 h, then cells were harvested for RNA isolation. GSK3-b activity in the OEA-derived cell line MDAH2774 was inhibited by treating 50% confluent cells with a final concentration of 10 nM SB216763 (Sigma, St Louis, MO, USA) whereas control cells were treated with DMSO. RNA was isolated at the indicated time points after initiation of treatment.
Immunohistochemical analysis of MSX2 and EMT marker expression in primary ovarian carcinomas Formalin-fixed paraffin-embedded tissue sections from 30 primary human OEAs that were included in our previous gene expression profiling studies Wu et al., 2007) were evaluated for MSX2 expression using immunohistochemistry. Tissues were obtained from the Cooperative Human Tissue Network/Gynecologic Oncology Group Tissue Bank and analyzed with approval from the Institutional Review Board of the University of Michigan Medical School (IRBMED 2002-0430) . Five-micron tissue sections were mounted on Probe-On slides (Fisher Scientific, Itasca, IL, USA), de-paraffinized in xylene and then rehydrated in distilled H 2 O through graded alcohols. Antigen retrieval was performed by microwaving the slides in citrate buffer (pH 6.0, Biogenex, San Ramon, CA, USA) for 10 min. Endogenous peroxidase activity was quenched by incubation with 3% hydrogen peroxide in methanol, then sections were blocked with 1.5% normal rabbit serum for 30 min. Sections were incubated with goat polyclonal anti-MSX2 (1:50 dilution, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) overnight at 4 1C. Slides were washed in phosphate-buffered saline, then incubated with a biotinylated rabbit anti-goat secondary antibody for 30 min at room temperature. Antigenantibody complexes were detected with the avidin-biotin peroxidase method using Vector DAB as a chromogenic substrate (Vectastain ABC kit, Vector Laboratories, Burlingame, CA, USA). Immunostained sections were lightly counter-stained with hematoxylin and then examined by light microscopy. Immunostaining was scored on a four-tiered scale for intensity (À, absent; ± , weak; þ , moderate; þ þ , strong) in the cell nucleus. Similar methods were used to evaluate E-cadherin, N-cadherin, Vimentin, Snail and Slug expression in representative primary OEAs with and without dysregulated b-catenin (n ¼ 6 per group). The following antibodies were employed for these studies: mouse monoclonal anti-Vimentin (1:1000, Dako, Carpinteria, CA, USA), anti-N-cadherin (1:500, Upstate, Lake Placid, NY, USA), anti-E-cadherin (1:200, Invitrogen), rabbit monoclonal anti-Snail or anti-Slug (1:50, Cell signaling, Beverly, MA, USA). Immunostaining was scored on a four-tiered scale for intensity (À, absent; ±, weak; þ , moderate; þ þ , strong) at the cell membrane for E-cadherin and N-cadherin, in the cytoplasm for Vimentin and in the nucleus for Snail and Slug.
MSX2 expression vector construction and transfection
Full length MSX2 cDNA (spanning nucleotides 89-892, GenBank accession #NM-002449.4) was generated by reverse transcriptase (RT)-PCR using total RNA from TOV112D cells. PCR primers were designed to include a Myc-epitope tag at the gene product's C-terminus. PCR products were subcloned into the retroviral vector pPGS-CMV-CITE-neo and the cDNA sequence of individual clones was verified by DNA sequencing. Selected cell lines were transduced with retroviral supernatant from amphotrophic Phoenix cells transfected with vector alone or vector with MSX2 cDNA. Stable polyclonal lines were generated by selection in G418 at a concentration of 0.8-1 mg/ml. After 1 week, the G418 concentration was reduced to 0.4-0.5 mg/ml, and expression of MSX2 protein was confirmed by western blot analysis.
ShRNA-mediated knockdown of MSX2 expression
To knock down MSX2 expression in the ovarian carcinoma cell lines TOV112D and TOV21G, three shRNAs targeting MSX2 were expressed using the lentiviral shRNAmir system (Human pGIPZ collection, Open Biosystems, Huntsville, AL, USA) or pSIREN-RetroQ (Clontech, Mountain view, CA, USA). The following sequences were introduced into the pGIPZ vector: human MSX2/sh1 (sense 5 0 -CGGCGCTCA TGTCCGACAAGAA-3 0 , anti-sense 5 0 -TTCTTGTCGGACA TGAGCGCCT-3 0 ); human MSX2/sh2 (sense 5 0 -AGCGCAA GTTCCGTCAGAAACA, antisense 5 0 -TGTTTCTGACGGA ACTTGCGCC-3 0 ); human MSX2/sh3 (sense 5 0 -CGCATCCT ACCCGTTCCATAGA-3 0 , antisense 5 0 -TCTATGGAACGG GTAGGATGCT-3 0 ). The pGIPZ MSX2/sh2 and MSX2/sh3 sequences were also used for ligation into the pSIREN-RetroQ vector. Stable polyclonal TOV112D and TOV21G cell lines expressing individual MSX2-specific (TOV112D/sh1, TOV112D/sh2) (TOV21G/sh2, TOV21G/sh3) or control shRNA (non-silencing shRNAmir (Open Biosystems)) were generated by transduction with lentiviral or retroviral supernatant, and grown in the presence of puromycin at a concentration of 1-1.25 mg/ml.
RNA isolation and quantitative RT-PCR
Total RNA from each cell line was extracted using standard procedures (Trizol reagent, Invitrogen). The cDNA was synthesized from 4 mg total RNA using a high capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). The qRT-PCR was performed with an ABI Prism 7700 Sequence Analyzer using SYBR green fluorescent protocol (Applied Biosystems). Each reaction was run in duplicate. The qRT-PCR reactions for target and internal control genes were performed in separate tubes. The comparative threshold cycle (C T ) method was used for the calculation of amplification-fold as specified by the manufacturer. Primer sequences for all target genes and HPRT1 (internal control) were shown in Supplementary Table S1 . PCR was performed in 25 ml reactions containing 1 Â SYBR Green PCR mix (Applied Biosystems), 200 nM of each primer and 0.5 ml of first strand cDNA. The PCR conditions were 50 1C for 2 min, 95 1C for 10 min, followed by 40 cycles of 95 1C 15 s, 60 1C 1 min. Each reaction was set up in duplicate and three separate measurements were carried out.
Western blot
Parental and stably transduced cells were lysed in cold RIPA lysis buffer containing proteinase inhibitors (complete proteinase inhibitors, Roche Applied Science, Indianapolis, IN, USA). Whole-cell lysates were analyzed by western blotting with mouse monoclonal anti-MSX2 antibody (Assay Designs) at 1:1000, anti-E-cadherin antibody (BD Biosciences, San Jose, CA, USA) at 1:5000, anti-Vimentin antibody (Dako) at 1:10 000 and rabbit monoclonal anti-N-cadherin antibody (Upstate) at 1:5000. Expression of b-actin was used as a loading control and was detected with anti-actin monoclonal antibody (Sigma).
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed using the Simple Chip Enzymatic Chromatin IP kit with magnetic beads according to the manufacturer's instructions (Cell Signaling).
Chromatin was immunoprecipitated with rabbit monoclonal anti-TCF4 antibody (Cell Signaling) or immunoglobulin G control antibody. Primers for the quantitative PCR are listed in Supplementary Table S1 .
Growth kinetics, focus formation, soft agar and tumorigenicity assays For cell proliferation assays, cells were seeded at 1 Â 10 4 /cm 2 in six-well plates in triplicate and were grown in complete medium for the duration of the assay. Medium was changed every three days. Cells were trypsinized and counted using a hemocytometer at the indicated time points. Three independent experiments were performed and error was calculated as the s.e. Focus formation and soft agar assays were performed using standard methods as described previously with the only modification that cells were plated in 12-well plates for the soft agar assay (Hendrix et al., 2006) . Mouse xenograft tumor growth was measured twice weekly after subcutaneous injection of 5 Â 10 6 cells in both flanks of Nu/Nu mice (Charles River, Wilmington, MA, USA). Tumor volume was estimated using the following formula: (length Â height Â width)/2.
Matrigel transmembrane invasion assays
Transwell invasion chambers (BD Biosciences, Bedford, MA, USA) with 8 mm pore inserts were used to perform in vitro invasion assays. A total of 5 Â 10 4 cells were plated in the upper chamber of 24-well invasion chambers and allowed to invade across the Matrigel-coated membrane for 48 h. Complete 10% fetal bovine serum medium was added to the bottom well as a chemoattractant. After non-invading cells were removed from the top of each membrane with wet cotton swabs, invading cells attached to the bottom of the membrane were fixed and stained with DAPI. The number of cells that penetrated the membrane was determined by counting the number of cells in five randomly selected Â 20 fields and calculating the mean. Experiments were performed in triplicate, and the assays were repeated at least once to verify results.
Chick embryo CAM invasion assays
Fertilized eggs were purchased from local poultry farms (Michigan State University, Lansing, MI, USA or Bilbie Aviaries, Ann Arbor, MI, USA). Embryos were incubated for 11 days at 37-38 1C with 60% humidity. Preparation of CAMs has been previously described . Briefly, to grow tumor masses, 2.5 Â 10 6 cells in 30 ml of Hank's Balanced Salt Solution were applied on the CAM. Cells were first infected with lentivirus expressing green fluorescent protein. After 3 days, the tumor masses and underlying CAM were excised and fixed with 4% paraformaldehyde in phosphatebuffered saline overnight at 4 1C. Frozen sections were cut from CAM tissues after immersion in 30% sucrose. The frozen sections were stained with mouse anti-laminin antibody (3H11, diluted 1:10, Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA) for 2 h, and then incubated with Alexa Fluor 594 conjugated goat anti-mouse immunoglobulin G secondary antibody (1:500; Invitrogen) for 60 min at room temperature. Sections were mounted with Vectashield mounting media with 4 0 -6 0 -diamidino-2-phenylindole (Vector Laboratories), monitored under a fluorescent microscrope and photographed with a high-resolution digital camera. Serial sections were also prepared and stained with hematoxylin and eosin for light microscopic examination.
Statistical analysis
Statistical analyses were performed using SPSS 10.0 (SPSS Inc., Chicago, IL, USA). For transwell invasion assays, statistical differences in cell invasion between groups were determined by the Mann-Whitney U test. For the qRT-PCR studies, statistical differences of expression between groups were calculated with the Student's t-test. Values were expressed as mean ± s.d. or mean ± s.e.m. In all cases, values of Po0.05 were considered significant.
